Disrupt Therapeutics

The UAB has granted a license over a co-owned patent to Disrupt Therapeutics S.L., a spin-off founded in Barcelona in 2023. The company is dedicated to developing a novel peptide drug to block the harmful effects of cannabinoids, combating cannabis addiction and mitigating the side effects of medical cannabis in chronic pain patients.